Professional Documents
Culture Documents
REVIEW ARTICLE
a
Department of Psychiatry, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
b
Jianan Mental Hospital, Tainan, Taiwan
c
College of Medical and Life Science, Chung Hwa University of Medical Technology, Taiwan
KEYWORDS Abstract Behavioral and psychological symptoms of dementia (BPSD) are common and debil-
Behavioral and itating problems, but current treatments are limited. Antipsychotic agents show some efficacy
psychological on BPSD, but their use is limited by the associated risk of cerebrovascular events and mortality.
symptoms of Reports have shown the efficacy of mood stabilizers on BPSD, but systemic reviews on this issue
dementia (BPSD); are scant. This article aims to review studies of the efficacy of mood stabilizers on BPSD, and
Dementia; the quality of the available evidence. We searched for articles published in English during the
Mood stabilizers; period 1990 to 2010 and included in the PubMed database that concerned treatment of BPSD
Review with mood stabilizers, such as carbamazepine, valproate, gabapentin, topiramate, lamotri-
gine, oxcarbazepine and lithium. The quality of the studies was assessed by considering the
trial designs, analyses, subjects and results. We found one meta-analysis and three randomized
controlled trials (RCTs) supporting the efficacy of carbamazepine in managing global BPSD,
particularly aggression and hostility. With regard to valproate, current evidence from one
meta-analysis and five RCTs did not strongly support its efficacy for global BPSD, including
agitation and aggression. Only open trials or case series showed some efficacy of gabapentin,
topiramate and lamotrigine in controlling BPSD. The single RCT investigating the effect of ox-
carbazepine on agitation and aggression showed negative results. Case series reports on
lithium tended to show it to be ineffective. Thus far, among mood stabilizers, carbamazepine
has the most robust evidence of efficacy on BPSD. More RCTs are needed to strengthen
evidence regarding the efficacy of gabapentin, topiramate and lamotrigine. Valproate, oxcar-
bazepine and lithium showed low or no evidence of efficacy. Large and well designed RCTs
focusing on specific symptoms of BPSD are needed to deal with the issue.
Copyright ª 2012, Elsevier Taiwan LLC. All rights reserved.
* Corresponding author. Jianan Mental Hospital, No. 80, Lane 870, Jhung-Shan Road, Rende District, Tainan City 71742, Taiwan.
E-mail address: d88904@gmail.com (W.-C. Ouyang).
AD Z Alzheimer’s disease; BPRS Z Brief Psychiatric Rating Scale; CGI Z Clinical Global Impressions; Dementia, NOS Z Dementia, not otherwise specified; n Z sample size; OAS Z Overt
Jadad
score
Impression (CGI). Scales developed specially for aggression
2
are the Overt Aggression Scale (OAS), Rating Scale for
Aggressive Behavior in the Elderly (RAGE) and the Social
Dysfunction and Aggression Scale-9 (SDAS-9) A scale
Aggression Scale; RAGE Z Rating scale for Aggressive behavior in the Elderly; RCT Z Randomized-controlled trial; VaD Z Vascular dementia.
Results
Agitation: BPRS-agitation
improved with treatment
Hostility: BPRS-hostility
Hostility: BPRS-hostility
Carbamazepine (CBZ)
Aggression: RAGE
One meta-analysis [13] and three RCTs [14e16] looked at
Aggression: OAS
CBZ monotherapy for BPSD (Table 1). With regard to global
BPSD, one RCT using a dose of 304 119 mg per day of CBZ
for 6 weeks showed efficacy (mean change on BPRS score
e7.7 5.7 vs. e0.9 6.3; p Z 0.0003; 95% CI for the dif-
ference Z 3.3w10.2; effect size Z 1.12) [15] but another
RCT using 400 mg per day CBZ did not [14]. A further meta-
analysis study merging the above two RCTs [14,15] and
Double-blind, placebo-controlled trials of carbamazepine monotherapy in dementia.
e5.5, 95% CI e8.5w e2.5) and CGI (odds ratio (OR) 10.2, 95%
6wk
6wk
8wk
CI 3.1w 33.1) [13]. With regard to hostility, two RCTs using
a mean dosage of 304e400 mg per day CBZ for 6 weeks
showed efficacy on the BPRS-hostility factor (mean change
e2.2 1.2 vs. e0.67 1.0; p Z 0.009; effect size Z 1.37
Daily dose
Fixed 400
Mean 304
Mean 600
and e2.5 2.4 vs. e0.3 2.3; p Z 0.0007; effect size Z
(mg)
51
n
of 304 mg per day CBZ for 6 weeks showed efficacy using the
BPRS-agitation factor (mean change e3.1 2.4 vs. e0.3
2.4; p Z 0.0001; effect size Z 1.15) [15].
Dementia,
Diagnosis
AD
AD
Double-blind,
Double-blind,
Study design
RCT
RCT
1998 [15]
1996 [16]
Olin et al.,
Valproate (VPA)
Dementia, NOS Z dementia, not otherwise specified; n Z sample size; NPI Z Neuropsychiatric Inventory; OAS Z Overt Aggression Scale; SDAS-9 Z Social Dysfunction and Aggression
AD Z Alzheimer’s disease; BMRS Z BecheRafaelsen Manic Scale; BPRS Z Brief Psychiatric Rating Scale; CGI Z Clinical Global Impressions; CMAI Z CoheneMansfield Agitation Inventory;
Jaded
score
3
3
4
Uncontrolled open trials, case reports or case series have
suggested the efficacy of VPA for variant BPSD [19e26],
Agitation/aggressiona: NPI-agitation/
improve with treatment over placebo
looking at the effect of VPA monotherapy on BPSD are listed
in Table 2. For global BPSD, three RCTs did not show
Aggression: SDAS-9
Global BPSD: BPRS
Agitation: CMAI
1000 mg per day of VPA for 6 weeks, showed efficacy using
Mania: BRMS
the CMAI scale (mean change e14.3 2.65 vs. e7.3 2.72;
p Z 0.035; effect size Z 2.60) [29]. This result was sup-
ported by that of another RCT with a Jadad score of three
and including 56 patients on 826 216 mg per day of VPA,
using the BPRS-agitation factor (p Z 0.05) [28]. However,
another RCT with a Jadad score of four and including 153
patients on a mean dosage of 800 mg per day of VPA showed
Agitation/aggression (NPI-agitation/aggression factor, CMAI) were more severe on valproate than placebo.
Randomized, double-blind, placebo-controlled trials of valproate monotherapy in dementia.
Agitation :CMAI
either [32]. For aggression, treatment with VPA achieved no
improvement in three RCTs [28e30] and even got worse in
another RCT [27]. For hostility, VPA showed negative results
in one RCT [28].
Meta-analysis in a Cochrane review showed VPA to have
more overall adverse effects (n Z 394; OR Z 1.99; 95%
CI Z 1.29e3.08) than placebo; these included sedation
(n Z 241; OR Z 2.48; 95% CI Z 1.37e4.47), gastrointestinal
Duration
6wks
3wks
6wks
6wks
tract infection (n Z 227; OR Z 3.02; 95% CI Z 1.04e8.80)
and thrombocytopenia (n Z 186; OR Z 7.91; 95%
CI Z 1.92e32.57). Although there was no significant
(375w1375)
(500e1000)
Daily dose
Fixed
Mean
Mean
Mean
1135
826
480
800
153
n
56
42
14
Dementia, NOS
VaD
VaD
AD
AD
AD
AD
AD
Gabapentin (GPN)
Porsteinsson et al., 2001 [28]
open trials and case series showed the efficacy of GPN for
BPSD as follows. One uncontrolled open trial in 12 patients
with variant types of dementia on a mean dose of 900 mg
per day GPN for 4 weeks did not show significant improve-
ment in global BPSD [34]. However, two case series
Table 2
CBZ Z carbamazepine; GPN Z gabapentin; LAM Z lamotrigine; Li Z lithium; MA Z meta-analysis; OXC Z oxcarbazepine; RCT Z randomized controlled trials; TOP Z topiramate; VPA Z valproate.
([) Significant effectiveness compared with placebo; (4) no significant effectiveness compared with placebo or symptoms more severe than with placebo; (Y) symptoms significantly worse than with placebo.
a
For CBZ, only meta-analyses or randomized controlled trials are listed.
b
Significant improvement in symptoms compared with pre-medication; no significant difference when compared with risperidone.
Table 4 Levels of recommendation of mood stabilizers on variant behavior and psychological symptoms of dementia (BPSD).
Global BPSD Hostility Aggression Agitation Manic symptoms Depressive symptoms
CBZ II II II II N/A N/A
VPA III N/Aa III III N/A N/A
GPN III N/A III III N/A N/A
TOP III N/A N/A III N/A N/A
LAM N/A N/A III III III III
OXC N/Aa N/A N/A N/A N/A N/A
Table 4. Overall, there is to date a lack of large and well on specific symptoms and dementia and using instruments
designed RCTs investigating the use of mood stabilizers in with better validity, to be carried out.
BPSD. Of all the mood stabilizers, CBZ has the most prom-
ising evidence of efficacy for global BPSD, especially for Conclusion
aggression and hostility. However, given the relatively
small body of clinical trial evidence, the high risk of
Thus far, not enough evidence supports the efficacy of
drugedrug interactions, and the known tolerability prob-
mood stabilizers in BPSD. Among all the mood stabilizers,
lems expected with long-term use, CBZ is not recom-
CBZ has shown the most promise, on the basis of current
mended for the routine treatment of agitation in patients
evidence. It can be used as second-line treatment in indi-
with dementia [63]. Early studies indicated that VPA was
viduals who are sensitive or unresponsive to antipsychotics.
possibly effective in agitation and aggression but RCTs in
However, drugedrug interaction or side effects should be
recent years have not supported this finding. Use of VPA to
watched for.
treat BPSD in dementia is not recommended, on the basis
of current evidence [63]. Open trials tended to support the
use of GPN for global BPSD and agitation; however, further Acknowledgments
RCTs are expected to strengthen evidence for its efficacy.
We do not recommend the use of TOP for BPSD, because of The authors thank the Taiwan Dementia Society and the
its adverse effect on cognition. LTG showed efficacy in Taiwanese Society of Geriatric Psychiatry for their financial
agitation, aggression, and manic and depressive symptoms support. We also acknowledge the contributions of experts
on open trials and further RCTs are needed. OXC is a rela- including Jen-Ping Huang, Jong-Ling Fuh, Cheng-Sheng
tively well tolerated drug but we found only one RCT, Chen and Chia-Fen Tsai.
which showed negative results. More trials of OXC are
anticipated. Some case series have shown Li to be effica-
cious for BPSD, but the results were conflicting, with most References
trials being carried out more than 20 years ago, and lacking
valid instruments. [1] Coen RF, Swanwick GR, O’Boyle CA, Coakley D. Behaviour
disturbance and other predictors of carer burden in Alz-
There was some evidence supporting the use of mood
heimer’s disease. Int J Geriatr Psychiatry 1997;12:331e6.
stabilizers in the management of BPSD. However, antipsy- [2] Steele C, Rovner B, Chase GA, Folstein M. Psychiatric symp-
chotics have more robust evidence for efficacy, although toms and nursing home placement of patients with Alz-
they increase the risk of mortality [63]. Treatment guide- heimer’s disease. Am J Psychiatry 1990;147:1049e51.
lines published in 2007 by the American Psychiatric Asso- [3] Murman DL, Colenda CC. The economic impact of neuropsy-
ciation advise that nonpharmacological management chiatric symptoms in Alzheimer’s disease: can drugs ease the
should be initiated before medicine is administrated, and burden? Pharmacoeconomics 2005;23:227e42.
that if medications are considered, antipsychotics are the [4] Alexopoulos GS, Streim J, Carpenter D, Docherty JP. Using
first option for psychosis or agitation, with mood stabilizers antipsychotic agents in older patients. J Clin Psychiatry 2004;
a second-line choice [63]. Our update review adds new 65(Suppl. 2):5e20.
[5] Ballard C, Waite J. The effectiveness of atypical antipsy-
information to the current treatment guidelines. Our find-
chotics for the treatment of aggression and psychosis in Alz-
ings suggest that CBZ is the most promising mood stabilizer heimer’s disease. Cochrane Database Syst Rev 2006:1e128.
in dementia with BPSD, especially for patients showing [6] US Food and Drug Administration. Antipsychotics, conventional
aggression and hostility. CBZ can be considered for patients and atypical. US Food and Drug Administration (FDA) www.
who are sensitive or unresponsive to antipsychotics, who fda.gov. www.fda.gov/Safety/MedWatch/SafetyInformation/
have significant cardiovascular risk factors and who are SafetyAlertsforHumanMedicalProducts/ucm110212.htm.
aggressive or hostile, but not delusional. [Accessed 10.02.10].
Our review of published studies has some limitations. [7] US Food and Drug Administration. Public Health Advisory:
First, there are few published large RCTs in this area. Deaths with antipsychotics in elderly patients with behavioral
Second, the use in studies of different outcome measures disturbances. US Food and Drug Administration (FDA) www.fda.
gov. www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafety-
makes it difficult to compare and integrate their findings
InformationforPatientsandProviders/DrugSafetyInformation-
for analysis. Third, many instruments lack validity and forHeathcareProfessionals/PublicHealthAdvisories/ucm053171.
reliability. Some studies used subjective measurements htm. [Accessed 11.07.10].
such as CGI or subjective judgment, which decreases the [8] Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ,
reliability of their findings. Some instruments used for Gavaghan DJ, et al. Assessing the quality of reports of
assessment in adults, such as BPRS, OAS and YMRS, lack randomized clinical trials: is blinding necessary? Control Clin
validity for older patients with dementia. Fourth, many Trials 1996;17:1e12.
trials include variant types of dementia, which increases [9] Haynes RB, Sackett DL, Guyatt GH, Tugwell P. Clinical epide-
the heterogeneity of the data. Past review articles on the miology: how to do clinical practice research. 3rd ed. New
efficacy of anticonvulsants in BPSD have focused on either York, NY: Lippincott Williams & Wilkins; 2006.
[10] Olivo SA, Macedo LG, Gadotti IC, Fuentes J, Stanton T,
overall BPSD [64,65] or only one symptom (e.g., aggression
Magee DJ. Scales to assess the quality of randomized controlled
or agitation) [66,67]. Fifth, trials focusing on safety were trials: a systematic review. Phys Ther 2008;88:156e75.
scant and our article lacks systematic evaluation of the [11] Hedges LV. Distribution theory for Glass’s estimator of effect
safety data. This is the first review article encompassing size and related estimators. J Educ Stat 1981;6:107e28.
the whole of BPSD and its individual symptoms. However, [12] Ebell MH, Siwek J, Weiss BD, Woolf SH, Susman J, Ewigman B,
there is a need for larger and better designed RCTs focusing et al. Strength of recommendation taxonomy (SORT):
192 Y.-C. Yeh, W.-C. Ouyang
a patient-centered approach to grading evidence in the [30] Sival RC, Haffmans PM, Jansen PA, Duursma SA,
medical literature. Am Fam Physician 2004;69:548e56. Eikelenboom P. Sodium valproate in the treatment of
[13] Ballard CG, Gauthier S, Cummings JL, Brodaty H, aggressive behavior in patients with dementiada randomized
Grossberg GT, Robert P, et al. Management of agitation and placebo controlled clinical trial. Int J Geriatr Psychiatry 2002;
aggression associated with Alzheimer disease. Nat Rev Neurol 17:579e85.
2009;5:245e55. [31] Tariot PN, Raman R, Jakimovich L, Schneider L,
[14] Olin JT, Fox LS, Pawluczyk S, Taggart NA, Schneider LS. A pilot Porsteinsson A, Thomas R, et al. Divalproex sodium in nursing
randomized trial of carbamazepine for behavioral symptoms home residents with possible or probable Alzheimer disease
in treatment-resistant outpatients with Alzheimer disease. complicated by agitation: a randomized, controlled trial. Am J
Am J Geriatr Psychiatry 2001;9:400e5. Geriatr Psychiatry 2005;13:942e9.
[15] Tariot PN, Erb R, Podgorski CA, Cox C, Patel S, Jakimovich L, [32] Lonergan E, Luxenberg J. Valproate preparations for agitation
et al. Efficacy and tolerability of carbamazepine for agitation in dementia. Cochrane Database Syst Rev; 2009:1e45.
and aggression in dementia. Am J Psychiatry 1998;155:54e61. [33] Porsteinsson AP. Divalproex sodium for the treatment of
[16] Cooney C, Mortimer ANN, Smith A, Newton K, Wrigley M. behavioural problems associated with dementia in the elderly.
Carbamazepine use in aggressive behavior associated with Drugs Aging 2006;23:877e86.
senile dementia. Int J Geriatr Psychiatry 1996;11:901e5. [34] Herrmann N, Lanctot K, Myszak M. Effectiveness of gabapentin
[17] Chambers CA, Bain J, Roshottom R, Ballinger BR, McLaren S. for the treatment of behavioral disorders in dementia. J Clin
Carbamazepine in senile dementia and overactivity: Psychopharmacol 2000;20:90e3.
a placebo, controlled double-blind trial. IRCS Med Sci 1982;10: [35] Dallocchio C, Buffa C, Mazzarello P. Combination of donepezil
505e6. and gabapentin for behavioral disorders in Alzheimer’s
[18] US Food and Drug Administration. Information for healthcare disease. J Clin Psychiatry 2000;61:64.
professionals: Dangerous or even fatal skin reactions - carba- [36] Raudino F, Mascalzi MG, Zagami A. Gabapentin and behavioral
mazepine (marketed as Carbatrol, Equetro, Tegretol, and disorders in severe Alzheimer disease. J Clin Psychopharmacol
generics). US Food and Drug Administration www.fda.gov. www. 2004;24:459e60.
fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformation- [37] Moretti R, Torre P, Antonello RM, Cazzato G. Gabapentin as
forPatientsandProviders/ucm124718.htm. [Accessed 01.03.11]. a possible treatment of behavioral alterations in Alzheimer
[19] Mellow AM, Solano-Lopez C, Davis S. Sodium valproate in the disease (AD) patients. Eur J Neurol 2001;8:501e2.
treatment of behavioral disturbance in dementia. J Geriatr [38] Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Gaba-
Psychiatry Neurol 1993;6:205e9. pentin for the treatment of behavioural alterations in
[20] Lott AD, McElroy SL, Keys MA. Valproate in the treatment of dementia: preliminary 15-month investigation. Drugs Aging
behavioral agitation in elderly patients with dementia. 2003;20:1035e40.
J Neuropsychiatry Clin Neurosci 1995;7:314e9. [39] Regan WM, Gordon SM. Gabapentin for behavioral agitation in
[21] Haas S, Vincent K, Holt J, Lippmann S. Divalproex: a possible Alzheimer’s disease. J Clin Psychopharmacol 1997;17:59e60.
treatment alternative for demented, elderly aggressive [40] Goldenberg G, Kahaner K, Basavaraju N, Rangu S. Gabapentin
patients. Ann Clin Psychiatry 1997;9:145e7. for disruptive behaviour in an elderly demented patient. Drugs
[22] Narayan M, Nelson JC. Treatment of dementia with behavioral Aging 1998;13:183e4.
disturbance using divalproex or a combination of divalproex [41] Sheldon LJ, Ancill RJ, Holliday SG. Gabapentin in geriatric
and a neuroleptic. J Clin Psychiatry 1997;58:351e4. psychiatry patients. Can J Psychiatry 1998;43:422e3.
[23] Herrmann N. Valproic acid treatment of agitation in [42] Low RAJ, Brandes M. Gabapentin for the management of
dementia. Can J Psychiatry 1998;43:69e72. agitation. J Clin Psychopharmacol 1999;19:482e3.
[24] Porsteinsson AP, Tariot PN, Jakimovich LJ, Kowalski N, Holt C, [43] Miller LJ. Gabapentin for treatment of behavioral and
Erb R, et al. Valproate therapy for agitation in dementia: psychological symptoms of dementia. Ann Pharmacother
open-label extension of a double-blind trial. Am J Geriatr 2001;35:427e31.
Psychiatry 2003;11:434e40. [44] Alkhalil C, Hahar N, Alkhalil B, Zavros G, Lowenthal DT. Can
[25] Sival RC, Duivenvoorden HJ, Jansen PA, Haffmans PM, gabapentin be a safe alternative to hormonal therapy in the
Duursma SA, Eikelenboom P. Sodium valproate in aggressive treatment of inappropriate sexual behavior in demented
behaviour in dementia: a twelve-week open label follow-up patients? Int Urol Nephrol 2003;35:299e302.
study. Int J Geriatr Psychiatry 2004;19:305e12. [45] Roane DM, Feinberg TE, Meckler L, Miner CR, Scicutella A,
[26] Forester B, Vanelli M, Hyde J, Perez R, Ahokpossi C, Rosenthal RN. Treatment of dementia-associated agitation with
Sribney W, et al. Report on an open-label prospective study of gabapentin. J Neuropsychiatry Clin Neurosci 2000;12:40e3.
divalproex sodium for the behavioral and psychological [46] Mowla A, Pani A. Comparison of topiramate and risperidone
symptoms of dementia as monotherapy and in combination for the treatment of behavioral disturbances of patients with
with second-generation antipsychotic medication. Am J Ger- Alzheimer disease: a double-blind, randomized clinical trial.
iatr Pharmacother 2007;5:209e17. J Clin Psychopharmacol 2010;30:40e3.
[27] Herrmann N, Lanctot KL, Rothenburg LS, Eryavec G. A [47] Fhager B, Meiri IM, Sjogren M, Edman A. Treatment of
placebo-controlled trial of valproate for agitation and aggressive behavior in dementia with the anticonvulsant
aggression in Alzheimer’s disease. Dement Geriatr Cogn Disord topiramate: a retrospective pilot study. Int Psychogeriatr
2007;23:116e9. 2003;15:307e9.
[28] Porsteinsson AP, Tariot PN, Erb R, Cox C, Smith E, Jakimovich L, [48] Aldenkamp AP. Cognitive effects of topiramate, gabapentin,
et al. Placebo-controlled study of divalproex sodium for agita- and lamotrigine in healthy young adults. Neurology 2000;54:
tion in dementia. Am J Geriatr Psychiatry 2001;9:58e66. 271e2.
[29] Tariot PN, Schneider LS, Mintzer JE, Cutler AJ, [49] Aldenkamp AP, Baker G, Mulder OG, Chadwick D, Cooper P,
Cunningham MR, Thomas JW, et al. Safety and tolerability of Doelman J, et al. A multicenter, randomized clinical study to
divalproex sodium in the treatment of signs and symptoms of evaluate the effect on cognitive function of topiramate
mania in elderly patients with dementia: results of a double- compared with valproate as add-on therapy to carbamazepine
blind, placebo-controlled trial. Current Therapeutic Research in patients with partial-onset seizures. Epilepsia 2000;41:
2001;62:51e67. 1167e78.
Review of mood stabilizers for BPSD 193
[50] Aldenkamp AP. Effects of antiepileptic drugs on cognition. [59] Dong X, Leppik IE, White J, Rarick J. Hyponatremia from
Epilepsia 2001;42(Suppl. 1):46e9. oxcarbazepine and carbamazepine. Neurology 2005;65:1976e8.
[51] Berkowitz AL, Semenchuk M. Effectiveness and tolerability of [60] Havens 2nd WW, Cole J. Successful treatment of dementia
lamotrigine for acute agitation and aggression in dementia. with lithium. J Clin Psychopharmacol 1982;2:71e2.
16th Annual Meeting. Honolulu, Hawaii: American Association [61] Randels PM, Marco LA, Ford DI, Mitchell R, Scholl M,
for Geriatric Psychiatry; 2003. Plesnarski J. Lithium and lecithin treatment in Alzheimer’s
[52] Aulakh JS, Hawkins JW, Athwal HS, Sheikh JI, Yesavage J, disease: a pilot study. Hillside J Clin Psychiatry 1984;6:
Tinklenberg JR. Tolerability and effectiveness of lamotrigine 139e47.
in complex elderly patients. J Geriatr Psychiatry Neurol 2005; [62] Holton A, George K. The use of lithium in severely demented
18:8e11. patients with behavioural disturbance. Br J Psychiatry 1985;
[53] Devarajan S, Dursun SM. Aggression in dementia with lamo- 146:99e100.
trigine treatment. Am J Psychiatry 2000;157:1178. [63] Rabins PV, American Psychiatric Association. Practice guide-
[54] De Leon OA. Treatment of psychotic symptoms with lamo- line for the treatment of patients with Alzheimer’s disease
trigine in Alzheimer disease. J Clin Psychopharmacol 2004;24: and other dementia. Am J Psychiatry 2007;164:5e56. 2nd ed.
232e3. [64] Konovalov S, Muralee S, Tampi RR. Anticonvulsants for the
[55] Ng B, Camacho A, Bardwell W, Sewell DD. Lamotrigine for treatment of behavioral and psychological symptoms of
agitation in older patients with dementia. Int Psychogeriatr dementia: a literature review. Int Psychogeriatr 2008;20:
2009;21:207e8. 293e308.
[56] Tekin S, Aykut-Bingol C, Tanridag T, Aktan S. Antiglutamatergic [65] Pinheiro D. Anticonvulsant mood stabilizers in the treatment
therapy in Alzheimer’s diseasedeffects of lamotrigine. Short of behavioral and psychological symptoms of dementia
communication. J Neural Transm 1998;105:295e303. (BPSD). Encephale [article in French] 2008;34:409e15.
[57] Sommer OH, Aga O, Cvancarova M, Olsen IC, Selbaek G, [66] Guay DR. Newer antiepileptic drugs in the management of
Engedal K. Effect of oxcarbazepine in the treatment of agitation/aggression in patients with dementia or develop-
agitation and aggression in severe dementia. Dement Geriatr mental disability. Consult Pharm 2007;22:1004e34.
Cogn Disord 2009;27:155e63. [67] Amann B, Pantel J, Grunze H, Vieta E, Colom F, Gonzalez-
[58] Kutluay E, McCague K, D’Souza J, Beydoun A. Safety and Pinto A, et al. Anticonvulsants in the treatment of aggression
tolerability of oxcarbazepine in elderly patients with epilepsy. in the demented elderly: an update. Clin Pract Epidemiol
Epilepsy Behav 2003;4:175e80. Ment Health 2009;5:14.